bioAffinity launches 2,000-patient FlowPath Lung study testing CyPath Lung in veteran, military populations

• bioAffinity Technologies announced new clinical data for its CyPath Lung diagnostic will be presented at the NAVREF 2026 conference on Sept. 27-30.
• One presentation describes clinical use cases where the test helped clarify lung nodule assessments, speeding decisions and reducing avoidable invasive procedures.
• A separate poster outlines an ongoing 2,000-patient longitudinal study in veteran and military populations to evaluate performance in real-world screening follow-up.
• The study uses at-home sputum collection to lower friction for participants, aiming to support broader adoption in federal healthcare settings.
• BioAffinity plans to jointly engage the federal market with new distributor AvMEDICAL during the conference, signaling a push to expand commercial reach.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609220800BIZWIRE_USPR_____20260922_BW400042) on September 22, 2026, and is solely responsible for the information contained therein.